Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy.

In conclusion, second line activity of ADT in AR-expressing, adenocarcinoma, NOS of salivary glands further strengthens the pathogenic and therapeutic role of AR signaling in AR-positive SGCs.
PMID: 24618694 [PubMed - as supplied by publisher]

Source: Cancer Biology and Therapy - March 11, 2014 Category: Cancer & Oncology Authors: Locati LD, Perrone F, Cortelazzi B, Imbimbo M, Bossi P, Potepan P, Civelli E, Rinaldi G, Quattrone P, Licitra L, Pilotti S Tags: Cancer Biol Ther Source Type: research